Company / Capital Expenditures
Processa Pharmaceuticals, Inc. Capital Expenditures History
FY2013-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.4K
FY2016
5-year range
$1.4K / $27.7K
FY2013-FY2016
Trend
-87.3%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has declined for 3 consecutive years, from $334,338 in FY2013 to $1,399 in FY2016.
Based on SEC 10-K filings.
$1,399 in FY2016 with a 3-year CAGR of -83.9%.
Declined from $27,674 to $1,399 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -83.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Processa Pharmaceuticals, Inc.'s capital expenditures has declined for 3 consecutive years.
- 3-year CAGR of -83.9%, indicating a declining trend.
- In FY2016, capital expenditures decreased 87.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | - | - |
| FY2021 | - | - |
| FY2016 | $1.4K | -87.3% |
| FY2015 | $11.0K | -60.2% |
| FY2014 | $27.7K | -91.7% |
| FY2013 | $334.3K | - |
As of FY2016 · SEC 10-K · Updated Jun 28, 2026